Update from Solid on microdystrophin gene therapy program

Solid Biosciences has provided an update to the community about SGT-003, their AAV-delivered microdystrophin gene therapy.  In the Phase 1/2 INSPIRE DUCHENNE clinical trial, 53 boys have been dosed, ranging from 6 months to 10 years old.  Solid has also started their Phase 3 IMPACT DUCHENNE trial, with sites currently enrolling in Australia and Canada.  Plans are progressing for sites in the US, UK, and Europe as well.  

Letter to the Duchenne Community (June 2026)